title: Formulation and evaluation of mouth dissolving tablets of the Etoricoxib.
abstract: The demand for mouth dissolving tablets has been growing during the last decade especially for elderly and children who have swallowing difficulties. Etoricoxib is a new non-steroidal anti-inflammatory drug (NSAID) with selective cox-2 inhibitory activity, selective inhibition of cox-2 provides anti-inflammatory and analgesic activity it is commonly used for osteo-arthritis, rheumatoid arthritis, primary dysmenorrhoea, post operative dental pain and acute gout. The main criteria for mouth dissolving tablets are to disintegrate or dissolve rapidly in oral cavity with saliva in 15 sec to 60 sec with need of water. The disintegrants used should fulfill the criteria by disintegrating the tablets in specified time limit.in the present investigation variety of super disintegrants like primogel, kollidone, Ac-Di-sol, L-HPMC, L-HPC, were selected and tablets were prepared by direct compression method in different concentration like 4% and 8%. The prepared tablets were evaluated for weight variation, hardness, friability, in vitro disintegration time, wetting time, in vitro dissolution study, etc. formulation f-9 shows the lowest disintegration time (44 sec) and wetting time (52 sec). In vitro dissolution studies revealed that formulation F-9 containing 8% L-HPC showed 97% drug release at the end of 20 min.
authors.affiliation: Vinayaka Missions College of Pharmacy, Vinayaka Missions University, Salem-636008, Tamilnadu, India. debjit_cr@yahoo.com
authors.forename: R Margret
authors.initials: RM
authors.lastname: Chandira
authors.forename: B S
authors.initials: BS
authors.lastname: Venkataeswarlu
authors.forename: M V
authors.initials: MV
authors.lastname: Kumudhavalli
authors.lastname: Debjitbhowmik
authors.forename: B
authors.initials: B
authors.lastname: Jayakar
mesh_terms: D000284:Administration, Oral; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004339:Drug Compounding / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D000077613:Etoricoxib; D005079:Excipients / Q000737:chemistry; D006801:Humans; D055595:Mechanical Phenomena; D009055:Mouth / Q000737:chemistry*; D011725:Pyridines / Q000008:administration & dosage*; D012995:Solubility; D013450:Sulfones / Q000008:administration & dosage*; D013607:Tablets / Q000737:chemistry
chemical_list: D005079:Excipients; D011725:Pyridines; D013450:Sulfones; D013607:Tablets; D000077613:Etoricoxib